Sulfatase-2: a prognostic biomarker and candidate therapeutic target in patients with pancreatic ductal adenocarcinoma

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is the fifth most common cause of cancer death in the UK. Its poor prognosis is attributed to late detection and limited therapeutic options. Expression of SULF2, an endosulfatase that modulates heparan sulfate proteoglycan 6-O-sulfation and is rep...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Br J Cancer
Autores principales: Alhasan, Sari F, Haugk, Beate, Ogle, Laura F, Beale, Gary S, Long, Anna, Burt, Alastair D, Tiniakos, Dina, Televantou, Despina, Coxon, Fareeda, Newell, David R, Charnley, Richard, Reeves, Helen L
Formato: Artigo
Lenguaje:Inglês
Publicado: Nature Publishing Group 2016
Materias:
Translational Therapeutics
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5046211/
https://ncbi.nlm.nih.gov/pubmed/27560551
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2016.264
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares